Kimryn Rathmell: ViPOR regimen is helping more B-cell lymphoma patients achieve full remission
Kimryn Rathmell shared a post on X:
“A new NCI study shows the ViPOR regimen, a non-chemotherapy treatment, is helping more B-cell lymphoma patients achieve full remission.
Dr. Christopher Melani shares more about this breakthrough.”
Christopher Melani, Staff Clinician and a clinical researcher at NCI, replied:
“Thanks for the shoutout! Amazing to see this regimen developed by researchers. CCR Lymphoma is changing the lives of our lymphoma patients.”
Source: Kimryn Rathmell/X and Christopher Melani/X
Dr. Kimryn Rathmell is a distinguished leader and researcher in the field of kidney cancer. Specializing in the research and treatment of complex and hereditary kidney cancers.
She has held leadership positions with organizations such as the American Society of Clinical Oncology and the American Society for Clinical Investigation, she has been elected to esteemed academies including the Association of American Physicians, the American Academy of Arts and Sciences, and the National Academy of Medicine.
Currently serving as the director of the National Cancer Institute, Dr. Rathmell continues to lead research initiatives and advance the understanding and treatment of kidney cancer, ultimately improving the lives of patients worldwide.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023